You are here: Industry Insights > Roivant

News List

Eisai Enters License Agreement with Roivant contractpharma
January 06, 2022
Grants the exclusive rights for global research, development, manufacture and sale of H3B-8800 to a subsidiary of Roivant Sciences Ltd
Roivant Releases Gimsilumab Trial Updates for ARDS Prevention, Treatment for COVID-19 Patients americanpharmaceuticalreview
May 20, 2020
Roivant Sciences announced several updates for its adaptive, randomized, double-blind, placebo-controlled, multi-center pivotal BREATHE trial ...
Sumitomo Dainippon and Roivant form $3bn alliance pharmaceutical-technology
September 10, 2019
Japan-based Sumitomo Dainippon Pharma has signed a memorandum of understanding (MoU) with healthcare technology company Roivant Sciences in a bid to provide new medicines to patients.
Roivant Announces Positive Results from Myovant's LIBERTY 1 Study americanpharmaceuticalreview
May 16, 2019
Roivant subsidiary Myovant Sciences announced positive topline results from its Phase 3 LIBERTY 1 trial of relugolix combination therapy in women with uterine fibroids.
Roivant Announces Positive Results from Myovant's LIBERTY 1 Study americanpharmaceuticalreview
May 15, 2019
Roivant subsidiary Myovant Sciences announced positive topline results from its Phase 3 LIBERTY 1 trial of relugolix combination therapy in women with uterine fibroids.
Roivant and Sinovant launch biopharma firm Cytovant Sciences pharmaceutical-technology
April 09, 2019
Roivant and Sinovant launch biopharma firm Cytovant Sciences
Roivant strikes broad pipeline pact with Daiichi fiercebiotech
December 25, 2018
Roivant has secured an option to license a stream of drugs from Daiichi Sankyo. The deal is the first time Roivant has formed a framework to facilitate the ongoing in-licensing of drugs from a company rather than picked up assets on an ad hoc basis.....
Roivant wins $200m backing to expand R&D operations pharmaphorum
December 11, 2018
Biotech startup Roivant has won a further $200 million backing from investors in a financing round valuing the company at $7 billion.
Roivant wins $200m backing to expand R&D operations pharmaphorum
December 03, 2018
Biotech startup Roivant has won a further $200 million backing from investors in a financing round valuing the company at $7 billion.
Roivant Sciences, iNtRON Bio Sign Licensing Deal for Novel Anti-Superbugs Biologic SAL200 americanpharmaceuticalreview
November 20, 2018
Roivant Sciences and iNtRON Biotechnology today announced that they have entered into a global licensing agreement for S

Previous page 1 2 Next page